Ruxolitinib sensitizes ovarian cancer to reduced dose Taxol, limits tumor growth and improves survival in immune competent mice

BACKGROUND: Chemotherapy initially reduces the tumor burden in patients with ovarian cancer. However, tumors recur in over 70% of patients, creating the need for novel therapeutic approaches. METHODS: We evaluated Ruxolitinib, an FDA-approved JAK 1/2 kinase inhibitor, as a potential adjunctive thera...

Descripción completa

Detalles Bibliográficos
Autores principales: Reeves, Patrick M., Abbaslou, Mojgan A., Kools, Farah R.W., Vutipongsatorn, Kritchai, Tong, Xiaoyun, Gavegano, Christina, Schinazi, Raymond F., Poznansky, Mark C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5706854/
https://www.ncbi.nlm.nih.gov/pubmed/29212208
http://dx.doi.org/10.18632/oncotarget.21541

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5706854/
https://www.ncbi.nlm.nih.gov/pubmed/29212208
http://dx.doi.org/10.18632/oncotarget.21541

Ejemplares similares